Hardean Achneck - 08 Oct 2024 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Medical Officer
Signature
/s/ Lesley Ann Calhoun, as attorney-in fact for Hardean Achneck
Issuer symbol
ALGS
Transactions as of
08 Oct 2024
Net transactions value
$0
Form type
4
Filing time
10 Oct 2024, 16:16:11 UTC
Previous filing
26 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 08 Oct 2024 Common Stock 75,000 $7.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty Five Percent (25%) of the shares subject to the option will vest on September 23, 2025 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.